Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (High-Risk) atherosclerotic patients in Sweden: A lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations

Applied Health Economics and Health Policy

Volumn 8, Issue 4, 2010, Pages 251-265

  Logman, J Floris S ^a   Heeg, Bart M S ^a   Herlitz, Johan ^b   Van Hout, Ben A ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

aspirin; clopidogrel; cost utility; myocardial infarction; prevention; stroke; therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; EMBOLISM PREVENTION; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LIFESPAN; MAJOR CLINICAL STUDY; MALE; SWEDEN; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; ASPIRIN; ATHEROSCLEROSIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; SWEDEN; TICLOPIDINE;

EID: 77954110993     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11535520-000000000-00000     Document Type: Article

References (50)

1. Davi G, Patrono C. Platelet activation and athero-thrombosis. N Engl J Med 2007; 357 (24): 2482-2494
2. The Swedish National Board of Health and Welfare. Statistics-health and diseases: myocardial infarctions in Sweden 1987-2005. Stockholm: Official statistics of Sweden, 2008
3. Truelsen T, Piechowski-Jozwiak B, Bonita R, et al. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13 (6): 581-598
4. Tran H, Anand S. Oral antiplatelet therapy in cerebrovas-cular disease, coronary artery disease and peripheral arterial disease. JAMA 2004; 292: 1867-1874
5. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-1339
6. Hirsh J, Bhatt D. Comparitive benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164: 2106-2110
7. Ringleb PA, Bhatt DL, Hirsch AT, et al., Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35 (2): 528-532
8. Carita P, Bego G. High-risk CAPRIE patients and CAPRIE-like CHARISMA patients: analysis on yearly event rates. Global Health Outcomes and Market Access (GHOMA). Paris: sanofi-aventis, 2006 (Data on File)
9. Heeg BM, Damen J, van Hout BA. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Pharmacoeconom-ics 2007; 25 (12): 1063-1082
10. The Dutch Institute for Healthcare Improvement (CBO). Treatment and prevention of coronary heart disease by lowering plasma cholesterol levels. Utrecht: CBO, 1998
11. Grobbee DE, Tuut MK, Hoes AW. CBO guideline 'high blood pressure' (revision). Ned Tijdschr Geneeskd 2001; 145 (43): 2071-2076
12. The Dutch Institute for Healthcare Improvement (CBO). Multi disciplinary guideline cardiovascular risk management. Utrecht: CBO, 2006
13. Heeg B, van Gestel A, van Hout B, et al. Cost-effectiveness of clopidogrel vs aspirin treatment in high-risk acute coronary syndrome patients in Denmark. Ugeskr Laeger 2006; 168 (35): 2911-2915
14. Heeg BM, Peters RJ, Botteman M, et al. Long-term clopi-dogrel therapy in patients receiving percutaneous coronary intervention. Pharmacoeconomics 2007; 25 (9): 769-782
15. Dutch Healthcare Insurance Board. Pharmacoeconomic report clopidogrel (Plavix®) 2004 [online]. Available from URL: http://www. cvz.nl/binaries/live/CVZ-Internet/hst-content/nl/documenten/cfh-rapporten/2004/ cfh040 6+clopidogrel-Plavix. pdf [Accessed 2010 May 16]
16. Norwegian Medicines Agency. Reimbursement report: clo-pidogrel (Plavix®) [online]. Available from URL: http://www.legemiddelverket.no/ upload/Refusjonsrapport%20% 20livslang%20behandling%20med%20klopidogrel%20til% 20%E2%80%A6.pdf [Accessed 2010 May 16]
17. Hollander D, Koudstraal P, Bots M, et al. Incidence, risk and case fatality of first ever stroke in the elderly population: the Rotterdam Study. J Neurol Neurosurg Psychiatry 2003; 74: 317-321
18. Yusuf S, Zhao F, Mehta SR, et al., the Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7): 494-502
19. Caro J, Migliaccio-Walle K, for the CAPRA study group. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. Am J Med 1999; 107 (6): 568-572
20. Mark D, Hlatky M, Califf R, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1424
21. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993; 13: 161-165
22. Hiatt MD. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardiol infarction: a decision analysis. Cardiology 1999; 91: 243-249
23. Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999; 246 (3): 309-316
24. Lee TT, Solomon N, Heidenreich PA, et al. Cost-effective-ness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997; 126: 337-346 (Pubitemid 27102517)
25. Pharmaceutical Benefits Board. Pharmaceuticals price database [online]. Available from URL: http://www.tlv.se/beslut/sok/lakemedel/[Accessed 2008 Apr 1]
26. Zethraeus N, Molin T, Henriksson P, et al. Costs of cor-onary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246: 151-159
27. Samsa GP, Bian J, Lipscomb J, et al. Epidemiology of re-current cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and costs. Stroke 1999; 30: 338-349
28. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clo-pidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Intern Med 2004; 255 (5): 562-570 (Pubitemid 38534869)
29. Ghatnekar O, Persson U, Glader EL, et al. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004; 20 (3): 375-380
30. Swedish National Board of Health and Welfare. Vardkostnader och vardtider 2001 for NordDRG-en sammanstallning av material fran Landstingsforbundets kostnadsdatabas 2001 [online]. Available from URL: http://www.skl.se/ MediaBinaryLoader.axd?MediaArchive- FileID=83c9114b-fb4a-4a4a-b90c-1e8062b1a9d2 [Accessed 2010 May 16]
31. Berg J, Lindgren P, Spiesser J, et al. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther 2007; 29 (6): 1184-1202
32. Statistics, Sweden. CPI, indices for main groups, annual avera-ges [online]. Available from URL: http://www.scb.se/Pages/TableAndChart-33908.aspx [Accessed 2010 May 16]
33. Pharmaceutical Benefits Board. General guidelines for eco-nomic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) [online]. Available from URL: http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf [Accessed 2010 May 16]
34. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16 (1): 33-64
35. Ekman M. Consumption and production by age in Sweden: basic facts and health economic implications. Studies in health economics: modelling and data analysis of costs and survival [dissertation]. Stockholm: Stockholm School of Economics, 2002 [online]. Available from URL: http://www.tlv.se/Upload/Foretag/ FOR-040506-tabell-lakemedel. pdf [Accessed 2010 May 16]
36. Fenwick E, O'Brien B, Briggs AH. Cost-effectiveness ac-ceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-415
37. Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopido-grel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin 2008; 24 (7): 2089-2101
38. Lindgren P, Stenestrand U, Malmberg K, et al. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005; 27 (1): 100-110
39. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17 (7): 1001-1007 (Pubitemid 26252516)
40. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101 (4): 366-371
41. Jonsson B, Carides GW, Burke TA, et al. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens 2005; 23 (7): 1425-1431
42. Persson U, Ramsberg J. Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions. Lakartidningen 2007; 104 (42): 3046-3050
43. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329 (7459): 224-227
44. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323 (7324): 1300-1303
45. Commission on Macroeconomics and Health. Macro-economics and health: investing in health for economic development. Geneva: WHO, 2001
46. Statistics Sweden. National accounts, quarterly and prelim-inary annual calculations: overview GDP per capita 1993-2009 [online]. Available from URL: http://www.scb.se/Pages/TableAndChart-219326.aspx [Accessed 2010 May 16]
47. Levy E, Gabriel S, Carita P, et al. An economic evaluation of clopidogrel in secondary prevention of ischemic events: high-risk populations [abstract]. Value Health 2002; 5: CV1
48. Rudelli G, Annemans L, Spiesser J, et al. An economic evaluation of clopidogrel vs aspirin in secondary prevention of ischemic events in high-risk atherothrombotic patients in Italy [abstract]. Value Health 2004; 7: CV6
49. Annemans L, Lamotte M, Levy E, et al. Cost-effectiveness analyis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ 2003; 6: 55-68
50. Berger K, Hessel F, Kreuzer J, et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin 2008; 24 (1): 267-74